TiumBio is experiencing a surge of over 8% in its stock price following the announcement of a US patent registration for its immuno-oncology candidate, Tosefosertib (TU2218), in combination therapy.
As of 2:48 PM on September 7, TiumBio's shares were trading at 4,730 won, up 360 won (8.24%) from the previous trading day, according to the Korea Exchange.
The company confirmed that it has completed the US patent registration for the combination therapy involving Tosefosertib.
This patent covers methods for preventing or treating tumors using Tosefosertib in combination with at least one of the major immune checkpoint inhibitors, such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, or lenvatinib.
Analysts view this as a significant step, as it secures exclusive rights for the development of combination therapies beyond just the ongoing clinical trials with pembrolizumab (Keytruda), encompassing a broad range of major immune checkpoint inhibitors.
The patent applies to various cancer types, including melanoma, breast cancer, pancreatic cancer, ovarian cancer, lung cancer, colorectal cancer, liver cancer, bile duct cancer, prostate cancer, kidney cancer, and head and neck cancer.
Additionally, the administration methods include not only oral administration but also intravenous (IV), subcutaneous (SC), and intramuscular (IM) injections. The administration of combination drugs can be in single or separate formulations, as well as simultaneous, sequential, or individual dosing.
TiumBio noted that the patent is valid until July 2042, with the potential for extension to July 2043 if the Patent Term Adjustment (PTA) system is applied.
The company stated, "This US patent strengthens the intellectual property rights for the combination therapy of Tosefosertib and Keytruda, currently in Phase 2a clinical trials, while also expanding the scope of rights for combination therapies with various immune checkpoint inhibitors and cancer types."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.